The FDA on October 23, 2025, approved BLENREP®, a B-Cell Maturation Antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with Bortezomib and Dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. BLENREP® is a product of GlaxoSmithKline.
Bottom Ad
Advertisement
Subscribe
